Skip to main content
Premium Trial:

Request an Annual Quote

Phase Genomics Wins $1.7M NIH Grant for Virus Discovery Platform Development

NEW YORK — Phase Genomics said on Tuesday that it has been awarded a $1.7 million grant from the National Institutes of Health to support its development of a platform for discovery of novel viruses that can be used to develop new therapeutics.

With the funding, Phase Genomics aims to use its sequencing-based proximity ligation, or Hi-C, technology to develop a reagent kit and accompanying analytical software for the culture-free assembly of viral genomes from metagenomic samples and associate these viruses with their microbial hosts.

Doing so will provide insights into antimicrobial resistance and help in the development of phage therapies, which use bacteriophages to treat infectious diseases, according to the Seattle-based company.

The platform is expected to be commercially available by mid-2021.

"Our new platform will offer pharmaceutical and microbiological researchers a valuable new dimension in understanding bacteriophage and their microbial hosts within complex microbial communities," Phase Genomics Cofounder and CEO Ivan Liachko said in a statement. "The application of this new platform will rapidly expand our understanding and the utility of phage on many facets of microbial biology and human health."

Phase Genomics said it has to date received $5.2 million in grants from the NIH, the US Department of Energy, and the Bill & Melinda Gates Foundation including two NIH grants worth a combined $3.9 million that were awarded in late 2020 for research on Hi-C assays for cytogenic applications.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.